Abstract:Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory domain (eg, CD28 or 4-1BB [TNFRSF9, also known as CD137]). The B-cell maturation antigen (BCMA; TNFRSF17) is an attractive target for CAR T-cell therapy because it is only expressed by normal and malignant plasma cells and by a subset of mature B cells. Several trials of anti-BCMA CAR T cells have shown high-quality responses, including minimal residual disease-negativity in patients with multiple myeloma who were heavily pretreated. Phase 3 trials are currently evaluating CAR T-cell therapy versus standard-of-care regimens in patients in earlier stages of the disease. Trials are also ongoing in newly diagnosed patients with high-risk cytogenetic profiles or with residual disease after transplantation. CAR T cells targeting other multiple myeloma antigens, such as CD19, CD38, CD138 (SYND1), and SLAMF7, are also being explored. Toxicities associated with CAR T cells include cytokine-release syndrome, different types of cytopenia, infections, and neurotoxicity. Although some subsets of patients have sustained responses for more than 1 year, most patients eventually relapse, which might be related to the loss of CAR T cells, loss of antigen expression on the tumour cell surface, or to an immunosuppressive microenvironment that impairs the activity of T cells. Efforts to improve the effectiveness of CAR T-cell therapy include optimising CAR design and adapting the manufacturing process to generate cell products enriched for specific subsets of T cells (eg, early memory cells). Other strategies explored in trials include dual-antigen targeting to prevent antigen escape and rational combination therapy to enhance persistence. Several approaches are also being developed to improve the safety of CAR T-cell therapy, such as the incorporation of a suicide gene safety system.

Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Current status of bispecific antibodies and CAR-T therapies in multiple myeloma

Chimeric Antigen Receptor T Cells For The Treatment Of Multiple Myeloma

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time

Chimeric Antigen Receptor T Cell Therapies for Multiple Myeloma

Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update

Bispecific Antibodies in the Treatment of Multiple Myeloma

T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape

CAR T therapies in multiple myeloma: unleashing the future

Multiple myeloma, immunotherapy and minimal residual disease

Updates on CAR T cell therapy in multiple myeloma

CAR T-cell therapy to treat multiple myeloma: current state and future directions

Adoptive cell therapy in multiple Myeloma

On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future

Bispecific antibodies for multiple myeloma: past, present and future

Current Advances in Chimeric Antigen Receptor T-cell Therapy for Refractory/relapsed Multiple Myeloma.

CAR T-cell therapy for multiple myeloma: state of the art and prospects

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting